Table 10.
Prevalence of Selected Drug Therapy at Baseline and Late Follow‐Up Among Subjects in the Upper Quartile of Risk for Coronary Heart Disease
| Drug | Baseline, N (%) | Follow‐Up, N (%)a | P Value |
|---|---|---|---|
| Insulin | 30 (24.2) | 52 (41.9) | <0.0001 |
| Aspirin | 99 (79.8) | 92 (75.4) | 0.011 |
| Clopidogrel | 3 (2.4) | 14 (11.9) | 0.001 |
| β‐Blocker | 38 (30.6) | 60 (50) | 0.0004 |
| ACEI/ARB | 87 (70.2) | 93 (78.2) | 0.005 |
| Ca channel blocker | 33 (26.6) | 50 (41.0) | <0.0001 |
| Diuretic | 40 (32.3) | 34 (28.8) | 0.029 |
| Statin | 94 (75.8) | 107 (89.9) | 0.15 |
| Ezetimibe | 4 (3.2) | 6 (5.0) | 0.012 |
| Fibrate | 18 (14.5) | 4 (3.4) | 0.44 |
ACEI, indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker.
a
N varies slightly due to some missing data, particularly in subjects who subsequently died.